** Canadian medical marijuana company Tilray’s shares up 1.7 pct, smallest gainer among peers, ahead of Q4 results after the bell
** Tilray’s third quarterly report as a public company to show Q4 revenue is higher, while loss narrows vs Q3 - Refinitiv IBES data
** Aurora Cannabis shares meanwhile reverse premarket losses to rise 3.2 pct after reporting Q2 results largely in line with estimates
** Eight Capital says ACB could “mildly outperform the group” on encouraging adult-use market share figures and reiteration of production ramp and EBITDA positive timelines
** Canopy Growth, in which Constellation Brands recently took a stake, up 3.1 pct
** WEED due to report Q3 results AMC on Valentine’s day, with revenue estimated to top $100 mln for first time
** Cronos up 3.3 pct and Aphria up 8.7 pct, leading gains among peers on the day
** But since a mid-July 2018 debut, TLRY shares have surged ~242 pct, outdoing all peers, while APHA’s ~12 pct rise is the least; CRON up ~197 pct in that time, WEED ~75 pct, ~ACB 32 pct (Reporting by Savio D’Souza)
Our Standards: The Thomson Reuters Trust Principles.